Your browser doesn't support javascript.
loading
A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis B.
Yuen, Man-Fung; Chen, Chi-Yi; Liu, Chun-Jen; Jeng, Wen-Juei; Elkhashab, Magdy; Coffin, Carla S; Kim, Won; Greenbloom, Susan; Ramji, Alnoor; Lim, Young S; Kim, Yoon J; Fung, Scott K; Kim, Dong J; Jang, Jeong-Won; Lee, Kwan Sik; Iyer, Radhakrishnan P; Macfarlane, Chelsea; Jackson, Kathy; Locarnini, Stephen A; Chan, Henry L Y; Afdhal, Nezam H.
Afiliação
  • Yuen MF; Department of Medicine & State Key Laboratory of Liver Research, Queen Mary Hospital, School of Clinical Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong.
  • Chen CY; Division of Gastroenterology and Hepatology, Department of Medicine, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.
  • Liu CJ; Department of Internal Medicine and Hepatitis Research Center, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan.
  • Jeng WJ; Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center, Chang Gung University, Taoyuan City, Taiwan.
  • Elkhashab M; Toronto Liver Centre, North York General Hospital, University of Toronto, Toronto, Canada.
  • Coffin CS; Cumming School of Medicine, University of Calgary, Calgary, Canada.
  • Kim W; Department of Internal Medicine, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center Seoul, Seoul, South Korea.
  • Greenbloom S; Toronto Digestive Disease Associates, Woodbridge, Canada.
  • Ramji A; Gastrointestinal Research Institute, Vancouver, Canada.
  • Lim YS; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Kim YJ; Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
  • Fung SK; Department of Medicine, University of Toronto, Toronto General Hospital, Toronto, Canada.
  • Kim DJ; Hallym University College of Medicine, Chuncheon, South Korea.
  • Jang JW; Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
  • Lee KS; Gangnam Severance Hospital, Yonsei University Health System, Seoul, South Korea.
  • Iyer RP; RIGImmune, Inc., New Haven, Connecticut, USA.
  • Macfarlane C; Spring Bank Pharmaceuticals, Hopkinton, Massachusetts, USA.
  • Jackson K; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Locarnini SA; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Chan HLY; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Sha Tin, Hong Kong.
  • Afdhal NH; Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Liver Int ; 43(1): 77-89, 2023 01.
Article em En | MEDLINE | ID: mdl-36300646
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatite B Crônica / Hepatite B Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatite B Crônica / Hepatite B Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article